4basebio

4basebio aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

CEO Dr Heikki Lanckriet. Courtesy – 4basebio.

The company accelerates the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. In July it raised $52.2m (£40m).

Career opportunities at 4basebio

Newsdesk

news@businessweekly.co.uk